{
    "2019-09-19": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Biogen's New Study to Test Higher Dose of SMA Drug Spinraza",
                "features": {
                    "keywords": [
                        "Biogen",
                        "SMA",
                        "Spinraza",
                        "Higher Dose",
                        "Study"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis has halted distribution of generic Zantac. Here's what you need to know.",
                "features": {
                    "keywords": [
                        "Novartis",
                        "halted",
                        "distribution",
                        "generic",
                        "Zantac"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO",
                "features": {
                    "keywords": [
                        "China Biologics",
                        "Buyout Offer",
                        "Provention Bio",
                        "Exagen IPO"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "British baby's death not due to SMA gene therapy -- Novartis",
                "features": {
                    "keywords": [
                        "British baby",
                        "death",
                        "SMA",
                        "gene therapy",
                        "Novartis"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}